Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genprex Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GNPX
Nasdaq
8731
https://www.genprex.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genprex Inc
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
- Apr 9th, 2024 12:31 pm
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
- Apr 4th, 2024 12:57 pm
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
- Apr 3rd, 2024 12:31 pm
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
- Apr 2nd, 2024 12:31 pm
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mar 22nd, 2024 8:10 pm
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mar 19th, 2024 5:24 pm
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
- Mar 12th, 2024 1:01 pm
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
- Mar 6th, 2024 1:30 pm
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
- Feb 7th, 2024 1:15 pm
Genprex to Present at Upcoming BIO CEO & Investor Conference
- Feb 6th, 2024 12:30 pm
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
- Feb 5th, 2024 12:30 pm
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
- Jan 31st, 2024 1:42 pm
Genprex Provides Business Update and Outlook for 2024
- Jan 5th, 2024 12:00 pm
Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer
- Nov 23rd, 2023 1:30 pm
Genprex to Present at BIO-Europe 2023
- Nov 3rd, 2023 1:00 pm
Genprex to Present at BIO-Europe 2023 Conference
- Nov 1st, 2023 11:30 am
Genprex Schedules, Hosts Virtual Key Opinion Leader Event
- Oct 20th, 2023 7:00 pm
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
- Oct 20th, 2023 11:30 am
Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference
- Oct 6th, 2023 1:00 pm
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 4th, 2023 4:00 pm
Scroll